Evidence map›Paper›PMID 31371743›Full record

ArticleScientific reports2019

Effect of immunosuppression in miRNAs from extracellular vesicles of colorectal cancer and their influence on the pre-metastatic niche.

Valeria Tubita, Joan Segui-Barber, Juan José Lozano, Elisenda Banon-Maneus, Jordi Rovira, David Cucchiari, Daniel Moya-Rull, Federico Oppenheimer, Hernando Del Portillo, Josep M Campistol and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Microrna Expression inMicroRNA (Shariqah, United Arab Emirates) · 2026
    Article
  3. Discovery of Donor-Derived Exosomal DNA as an Exploratory Biomarker of Kidney Graft Rejection: A Cross-Sectional Study.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Valeria TubitaLaboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS, Barcelona, Spain.
Joan Segui-BarberInstituto de Salud Global de Barcelona (ISGlobal), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Juan José LozanoBioinformatics Platform, CIBEREHD, Barcelona, Spain.
Elisenda Banon-ManeusLaboratori Experimental de Nefrologia i Trasplantament (LENIT), FCRB, Barcelona, Spain.
Jordi RoviraLaboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS, Barcelona, Spain.ORCID http://orcid.org/0000-0001-8737-5005
David CucchiariDepartment of Nephrology and Renal Transplantation, ICNU, Hospital Clínic, Barcelona, Spain.
Daniel Moya-RullLaboratori Experimental de Nefrologia i Trasplantament (LENIT), FCRB, Barcelona, Spain.
Federico OppenheimerLaboratori Experimental de Nefrologia i Trasplantament (LENIT), FCRB, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1117-831X
Hernando Del PortilloInstituto de Salud Global de Barcelona (ISGlobal), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5278-3452
Josep M CampistolLaboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS, Barcelona, Spain.
Fritz DiekmannLaboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS, Barcelona, Spain.
Maria José Ramirez-BajoLaboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS, Barcelona, Spain. mramire1@clinic.cat.
Ignacio RevueltaLaboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS, Barcelona, Spain. irevuelt@clinic.cat.ORCID http://orcid.org/0000-0002-3584-4516
Instituto de Salud Carlos III · ESHospital Clínic de Barcelona · ESBarcelona Institute for Global Health · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESInstitució Catalana de Recerca i Estudis Avançats · ESSpanish Clinical Research Network · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) occurs with more aggressiveness in kidney transplant recipients compared to the general population. Immunosuppressive therapy plays a crucial role in the development of post-transplant malignancy. Concretely, cyclosporine A (CsA) has intrinsic pro-oncologic properties, while several studies report a regression of cancer after the introduction of rapamycin (RAPA). However, their effect on the extracellular vesicle (EV) content from CRC cell lines and their relevance in the pre-metastatic niche have not yet been studied. Here, we investigated the effect of RAPA and CsA in EV-miRNAs from metastatic and non-metastatic CRC cell lines and the role of relevant miRNAs transferred into a pre-metastatic niche model. EV-miRNA profiles showed a significant upregulation of miR-6127, miR-6746-5p, and miR-6787-5p under RAPA treatment compared to CsA and untreated conditions in metastatic cell lines that were not observed in non-metastatic cells. From gene expression analysis of transfected lung fibroblasts, we identified 22 shared downregulated genes mostly represented by the histone family involved in chromatin organization, DNA packaging, and cell cycle. These results suggest that EV-miR-6127, miR-6746-5p and miR-6787-5p could be a potential epigenetic mechanism induced by RAPA therapy in the regulation of the pre-metastatic niche of post-transplant colorectal cancer.

Indexed as

Cell Line, TumorColonic NeoplasmsCyclosporineEpigenesis, GeneticExtracellular VesiclesGene Expression ProfilingHumansImmunosuppression TherapyMicroRNAsSirolimusTranscription, GeneticCyclosporineMicroRNAsSirolimus

Identifiers

PMID31371743
PMCPMC6672014
OpenAlexW2964687666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.